10th Annual Neuroscience Innovation Forum

10th Annual Neuroscience Innovation Forum

FOR BUSINESS DEVELOPMENT, LICENSING & INVESTMENT

10th of January 2027|MARINES' MEMORIAL CLUB | SAN FRANCISCO | USA

We are pleased to announce that the 10th Annual Neuroscience Innovation Forum (#Sachs_NIF) will take place once again at the Marines Memorial Club, San Francisco on the 10th of January 2027, a day before the JP Morgan meeting and the Virtual Week will follow from the 19th – 21st of January. In addition, building on the success of previous events, the 3rd Annual Obesity & Cardiometabolic Innovation Forum (#Sachs_OCIF) will take place the day before on the 9th of January 2027, offering relevant attendees the opportunity to register for both events.

Positioned at the beginning of JPM week, the NIF forum focuses on the latest developments across key areas of neuroscience, which are currently attracting record investor interest and deal flow. The main programme for the 10th Annual NIF will feature more than 8 hours of high-level keynotes and panel discussions addressing the important advances in therapeutic, neurotech, and diagnostics fields. 

The target audience consists of buy and sell-side analysts from investment banks and funds, alongside partnering executives from pharma, Biotech, MedTech, Neurotech, and diagnostics companies. We anticipate around 400 delegates in-person and 30+ company presentations by established and emerging companies. This will include a limited number of live presentations taking place in dedicated presentation tracks, alongside virtual company showcases, which will be available on demand. Recorded sessions will also be added on demand on the Event Portal during the virtual week. 

The in-person meetings will be taking place on the 10th of January, while virtual meetings will take place on the 19th – 21st of January. For the virtual meetings, the system will allow you to have a secure audio/video call, as well as the option to present slides using a screen share function, and we will have a dedicated room for in-person meetings. The conference will be held in the Pacific Standard Time (PST) zone. 
 
The physical programme will consist of the usual panels and keynotes, which will be available on demand for the virtual audience, the week after the JP Morgan meeting. Additionally, there will be pre-arranged in-person meetings, live and on-demand company showcases, and a reception. The in-person event will be followed by an additional week of virtual meetings available through the audio/video Online Meeting System, starting from the 19th of January.

CONTRIBUTING SPONSORS:

Ladenburg Thalmann & Co. Inc.
NRx Pharmaceuticals, Inc.

Panels & Sessions on the 10th of January Include:

  • Neuroscience Dealmaking Panel: What's Next for 2027
  • Industry Overview Keynote Speech
  • Investing in Alzheimer's & Dementia Panel: Advances in Drug Development & Diagnostics
  • Keynote Speech
  • Progress in PD, Movement Disorders & Related Conditions Panel
  • Keynote Speech 
  • The Neuropsychiatry Renaissance Panel: New Targets, New Therapies
  • Psychedelics 2027 Panel: Where Does the Field Stand
  • New Directions in Neurotechnology Panel: Devices, Therapeutics & Wellness
  • Longevity Meets Neuroscience Panel: Where Investors Are Looking Next

In-Person Meetings:

  • 10th of January

Online Virtual Meetings:

  • 19th – 21st of January

Reception:

  • 10th of January

Keynote Speakers:

Harry Tracy
President, NI Research Inc.

Chairs & Speakers:

Aaron Nelson
Partner, Venture Investments, Novo Holdings US Inc.
Alex Colville
General Partner, Age1 Capital Management, LLC
Alexander Gebauer
Co-Founder & Executive Chairman, Galimedix Therapeutics, Inc.
Amit Etkin
Founder & CEO, Alto Neuroscience Inc.
Anna Lisa Picciolo-Lehrke
Head of Business Development Neurology, UCB Pharma
Avram Fraint
Senior Director, Clinical Science & External Affairs, Aspen Neuroscience, Inc.
Bruce Leuchter
President & CEO, Neurvati Neurosciences, Inc.
Carla Lema Tomé
Head of Neuroscience Search & Evaluation, AbbVie, Inc.
Celine Bouquet
Global SnE Head and Basel BD Head, Neuroscience, Ophthalmology and Rare Diseases, F. Hoffmann-La Roche AG
Chris Hoyt
CEO, KeifeRx LLC
Chris Stern
Managing Director, L.E.K. Consulting
Daniel Lee
Partner, PJT Partners
Diana Saraceni
Co-Founder & General Partner, Panakès Partners SGR SpA
Gaia Skibinski
VP & Head of Translational Therapeutics, The Michael J. Fox Foundation for Parkinson's Research
Gregor Macdonald
VP, Head of BD & Licensing, Search & Assessment, H. Lundbeck A/S
Jackie von Salm
Co-Founder & Chief Scientific Officer, Psilera Inc.
Jay Olson
Managing Director & Senior Analyst, Oppenheimer & Co. Inc.
Jeff Cohen
Director of Research, Ladenburg Thalmann & Co. Inc.
Jim Ray
Executive Director, Neuroscience, UT MD Anderson
Joseph Tucker
CEO, Enveric BioSciences, Inc.
Kabir Nath
CEO, Compass Pathways
Karen LaRochelle
SVP, Global Business Development & Strategy, Merz Therapeutics GmbH
Ken Mariash
CEO, Sinaptica Therapeutics, Inc.
Klaus Dugi
CEO, Vandria SA
Laszlo Kiss
CBO & Head of Research, Gilgamesh Pharmaceuticals
Laura Nisenbaum
Interim Chief Science Officer, Alzheimer's Drug Discovery Foundation
Lisa Ricciardi
President & CEO, Cognition Therapeutics, Inc.
Manuel López-Figueroa
Scientific Liaison, Pritzker Neuropsychiatric Disorders Research Consortium
Marianne Mertens
Partner, Apollo Health Ventures
Matt Adams
CEO, BrainScope Company Inc.
Murali Gopalakrishnan
Global Head, Neuroscience Search & Evaluation, Corporate Strategy Office, AbbVie, Inc.
Peng Leong
CBO & Head of Brain Aging, BioAge Labs, Inc.
Ryan Dawes
Corporate Development | Search & Evaluation Neuroscience, Biogen
Sahil Kirpekar
CEO, Reunion Neuroscience, Inc.
Seth Lederman
Chairman & CEO, Tonix Pharmaceuticals Holding Corp.
Spring Behrouz
CEO, Vincere Biosciences Inc.
Stephen Zicha
Neuroscience - Search and Evaluation, Eli Lilly and Company
Steven Dickman
CEO, CBT Advisors
Sumant Kulkarni
Managing Director, Biotechnology Equity Research, Canaccord Genuity LLC

More TBA...

Presenting Companies:

Ab Studio Inc. logo
Acelot, Inc. logo
Alzinova AB logo
Aprecia Pharmaceuticals logo
Ariadne Bio logo
Beacon Biosignals, Inc. logo
BrainScope Company Inc. logo
BrainStorm Therapeutics, Inc. logo
Cognition Therapeutics, Inc. logo
Enveric BioSciences, Inc. logo
Galimedix Therapeutics, Inc. logo
Harness Therapeutics Ltd. logo
KeifeRx LLC logo
Kinoxis Therapeutics Pty Ltd logo
Lobe Sciences Ltd. logo
Merz Therapeutics GmbH logo
Neuro-Innovators, Inc. logo
Nissan Chemical America Corporation logo
Oculis SA logo
Ondura Biosciences logo
Osmind logo
PgRx Corporation logo
Psilera Inc. logo
QurCan Therapeutics Inc. logo
Saniona A/S logo
Sinaptica Therapeutics, Inc. logo
Spark Biomedical, Inc. logo
Stand Up Therapeutics Inc. logo
Stream Neuroscience Inc. logo
Tonix Pharmaceuticals Holding Corp. logo
Vandria SA logo
VersaPeutics Inc.
Vincere Biosciences Inc. logo

Previous Highlights:

10th Annual Neuroscience Innovation Forum event highlight
10th Annual Neuroscience Innovation Forum event highlight
10th Annual Neuroscience Innovation Forum event highlight
10th Annual Neuroscience Innovation Forum event highlight
10th Annual Neuroscience Innovation Forum event highlight

To learn more about presenting, exhibiting or sponsorship opportunities, please contact us at [email protected] or call us on + 44 203 463 4890.

SACHS ASSOCIATES SWITZERLAND AG

Aeschenvorstadt 4
Basel | CH-4051
Switzerland

SACHS ASSOCIATES LTD.

3rd floor, 89-90 Paul Street
London | EC2A 4NE
United Kingdom
Privacy Policy

© COPYRIGHT 2026. ALL RIGHTS RESERVED.